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Abstract 
The ability to classify people according to their underlying genetic susceptibility to a 
disease is increasing with new knowledge, better family data, and more sophisticated risk 
prediction models, allowing for more effective prevention and screening. But to do so we 
need to know if risk associations are the same for people with different genetic 
susceptibilities. To illustrate one way to estimate such gene–environment interactions, we 
used prospective data from three Australian cancer family cohorts, two enriched for familial 
risk of breast cancer. There were 288 incident breast cancers in 9,126 participants from 3,222 
families. We used Cox proportional hazards models to investigate whether breast cancer 
associations with body mass index at age 18 to 21 years, body mass index at baseline, and 
change in body mass index, differed according to genetic risk based on lifetime breast cancer 
risk from birth estimated by the Breast and Ovarian Analysis of Disease Incidence and 
Carrier Estimation Algorithm adjusted for age at baseline data collection. Although no 
interactions were statistically significant, we have demonstrated the power with which gene–
environment interactions can be investigated using a cohort enriched for individuals with 
increased genetic risk and a continuous measure of genetic risk based on family history. 
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Abbreviations 
ABCFR  Australian Breast Cancer Family Registry 
ACCFR Australian Colorectal Cancer Family Registry 
BOADICEA Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation 
Algorithm 
BMI body mass index 
CI confidence interval 
HR  hazard ratio 
kConFab  Kathleen Cuningham Foundation Consortium for Research into Familial 
Breast Cancer 
SD standard deviation 
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The ability to classify people according to their underlying genetic susceptibility to a 
specific disease is increasing with new knowledge on genetic risk factors, better family data, 
and more sophisticated risk prediction models. This opens up the potential for more effective 
prevention and screening. But to do so, we need to know if risk associations are the same for 
people with different genetic susceptibilities. 
Taking breast cancer as an example, current information from mutation screening (1) 
and multiple markers of genetic susceptibility (including single nucleotide polymorphisms 
[SNPs]) (2), especially when combined with multi-generational family cancer history (3), can 
be used to develop risk predicting scores with an inter-quartile risk ratio of 5 or more (3). The 
cost of measuring genetic markers is decreasing and classification of risk is likely to improve 
by using genetic risk scores that are based on more markers, and perhaps using by using 
alternative approaches to the usual statistical significance of individual markers to choose 
them.  
The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation 
Algorithm (BOADICEA) estimates genetic risk by modeling major genes and polygenes (3-
5). BOADICEA has been shown to be well calibrated and have good discriminatory accuracy 
for Australian women (6). BOADICEA is being extended to include more measured genetic 
and environmental or lifestyle risk factors, including mammographic density (7, 8).  
A woman’s risk of breast cancer depends on both her underlying genetic predisposition 
and some environmental and lifestyle factors she experiences during her lifetime. Few 
epidemiological studies of breast cancer have measured both genetic and non-genetic risk 
factors comprehensively, and fewer have addressed gene–environment interactions by using 
global measures of genetic risk based on complex models of multi-generational family data 
(as distinct from considering individual measured genetic markers of risk). Moreover, 
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previous studies of gene–environment interactions have not used samples enriched for 
familial risk, which limits power to detect differences across the full spectrum of risk (9). 
Environmental and lifestyle risk factor associations could be stronger or weaker for 
women at higher genetic risk of breast cancer than for women at a lower genetic risk of breast 
cancer. Such gene–environment interactions could result in substantial gradients in absolute 
risk for women at increased genetic risk of breast cancer and make it possible to better 
identify women at high risk who might benefit from additional screening or preventive 
measures appropriate for their risk. Finding gene–environment interactions could also show 
that some risk factors for women in the general population do not apply to women at high 
genetic risk. On the other hand, a lack of evidence for a gene–environment interaction from 
studies with sufficient power would mean that a modifiable risk factor for women in the 
general population, who are mostly at very low risk, is also important for women at the 
higher end of genetic risk. Either way, clarification of the issue of gene–environment 
interactions is important. 
To illustrate one way to find evidence for gene–environment interactions, we used a 
prospective family cohort enriched for familial risk (10) to investigate whether associations 
between breast cancer risk and body mass index (BMI) differ according to a woman’s 
underlying genetic risk of breast cancer. We chose the Breast and Ovarian Analysis of 
Disease Incidence and Carrier Estimation Algorithm (BOADICEA) to estimate genetic risk 
because, being founded on likelihood theory, it makes optimal use of family data and can be 
continually updated to include new risk information, such as genetic risk scores based on 
SNPs.  
We chose BMI because it is an example of a potentially modifiable continuous risk 
factor for which we had two correlated measurements: one in early adulthood and one in later 
life. Using this example, we consider the issue of multiple risk factors and allow for the 
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possibility that the interactions can differ. We chose to fit multiplicative interactions to 
demonstrate our approach because they are standard, appreciating that other models such as 
those including data from SNPs could have been fitted. 
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MATERIALS AND METHODS 
Subjects 
We studied women who were unaffected with invasive breast cancer at enrolment into 
three large Australian cancer family cohort studies: the Australian Breast Cancer Family 
Registry (ABCFR), the Kathleen Cuningham Foundation Consortium for Research into 
Familial Breast Cancer (kConFab), and the Australasian Colorectal Cancer Family Registry 
(ACCFR). 
ABCFR. From 1992 to 1999, probands and their relatives were recruited as described 
previously (11-16). Briefly, probands included population-based cases aged less than 60 
years when diagnosed with incident first primary invasive breast cancer (identified through 
population-complete cancer registries); population-based controls aged less than 60 years at 
recruitment (identified through the electoral roll to which registration is mandatory for 
Australian adults); Ashkenazi Jewish women with a family history of breast cancer; and twin 
pairs (identified through the Australian Twin Registry) for which one or both had breast 
cancer. Living adult first-degree relatives, aunts and grandparents were invited to participate, 
and additional recruitment occurred iteratively; if identified relatives had a diagnosis of breast 
cancer, participation was sought from them and their first-degree relatives (13, 14).  
At baseline, all participants completed an interviewer-administered risk factor 
questionnaire that asked about their demographic background, personal characteristics, 
reproductive history, environmental risk factors, lifestyle risk factors, surgeries, and personal 
history of breast and other cancers (12, 14). Participants were also asked to provide cancer 
history information on all of their first-degree and second-degree relatives (12, 14). This 
ensured that cancer information was obtained from multiple sources and that, for each 
individual, cancer history was usually self-reported or reported by a first-degree relative. 
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Verification of cancers was sought through pathologist reviews of cancer tissue, pathology 
reports, cancer registries, medical records, and death certificates (12, 14). 
Participants were re-contacted at approximately 10 years and 15 years after their 
baseline interview and invited to take part in the follow-up phase of the ABCFR. The follow-
up questionnaires were either interviewer-administered during a telephone interview or self-
administered with a telephone interview to obtain additional details if required. The follow-
up questionnaires updated the data collected in the baseline questionnaire and participants 
were also asked to provide an updated cancer history for their first-degree and second-degree 
relatives and the date of death for any deceased relatives. Where possible, reports of new 
cancer diagnoses were verified using pathology reports and medical records. 
Ethics approval for the ABCFR was obtained from the Human Research Ethics 
Committees of the University of Melbourne and the Cancer Councils of Victoria and New 
South Wales. All participants provided written informed consent before taking part in the 
research.  
kConFab. Starting in 1997, families with multiple cases of breast cancer were recruited 
as described previously (17). Briefly, eligible families were identified from women attending 
clinical consultations at 24 family cancer clinics in Australia and New Zealand. Eligible 
families included those with a strong family history of breast or ovarian cancer, or a 
confirmed mutation in the breast cancer 1, early onset (BRCA1) or breast cancer 2, early 
onset (BRCA2) genes (18). At baseline, participants provided a blood sample for genetic 
analyses and completed the questionnaire used by the ABCFR (14). 
Every three years, all female participants are invited to participate in the kConFab 
follow-up study, as described in detail previously (19). This study used a mailed self-
administered questionnaire to systematically update the baseline questionnaire data, personal 
cancer history, family cancer history, environmental risk factors, lifestyle risk factors, and 
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uptake of cancer prevention and screening strategies. When possible, self-reports of new 
cancer diagnoses and prophylactic surgeries were verified using pathology reports and 
medical records. 
Ethics approval for kConFab was obtained from the coordinating site at Peter 
MacCallum Cancer Centre and from each of its recruitment sites. All participants provided 
written informed consent before taking part in the research. 
ACCFR. From 1998 to 2007, families were recruited to study of the genetic, 
environmental, and lifestyle factors associated with colorectal cancer, as described previously 
(20, 21). In brief, probands included men and women who were aged less than 60 years when 
diagnosed with incident first primary invasive colorectal cancer (identified from the 
population-complete Victorian Cancer Registry) and affected and unaffected individuals with 
a family history of colorectal cancer or related cancers who were recruited from family 
cancer clinics in Australia and New Zealand.  
For all probands, their living adult first-degree and second-degree relatives were invited 
to participate. If an identified relative had a diagnosis of colorectal cancer or a related cancer, 
participation was sought from them and their first-degree relatives. 
At baseline, all participants completed a questionnaire that asked about their 
demographic background, personal characteristics, medical history, medication use, 
reproductive history (for females), physical activity, diet, smoking, alcohol use, and personal 
history of cancer (20). The questionnaire used by the ACCFR (22) was based on the 
questionnaire used by the ABCFR and kConFab. Participants were also asked to provide 
cancer history information on all of their first-degree and second-degree relatives so that 
cancer history was obtained from multiple sources. Verification of cancers was sought 
through pathology reports, medical records, cancer registries and death certificates (20). 
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Participants have been followed up approximately every five years and asked to 
complete a self-administered questionnaire to update data the information collected at 
baseline and to provide updated cancer histories for their first-degree and second-degree 
relatives (21, 23). Where possible, reports of new cancer diagnoses were verified using 
pathology reports and medical records. 
Ethics approval for the ACCFR was granted by the Human Research Ethics Committee 
at the University of Melbourne. 
Eligibility. For the present study, female ABCFR and kConFab participants were 
eligible if they had not been diagnosed with invasive breast cancer at baseline; they had not 
had a mastectomy (unilateral or bilateral) before baseline; they had not had an oophorectomy 
before baseline (unilateral or bilateral); they and their family had no deleterious mutations in 
BRCA1, BRCA2, or the tumor protein p53 (TP53) gene; they had completed a baseline 
questionnaire and provided data for all the height and weight questions. ABCFR participants 
were included if at least one member of their family had completed a follow-up 
questionnaire, while the kConFab participants were included if they had completed at least 
one follow-up questionnaire.  
Female ACCFR participants were eligible if they had not been diagnosed with invasive 
breast cancer at baseline; they had completed a baseline questionnaire and provided valid 
data for the height and weight questions; and if at least one member of their family had 
completed a follow-up questionnaire. It was not possible to exclude women who had had a 
mastectomy or oophorectomy before baseline because this information was not collected. The 
ACCFR did not test for mutations in BRCA1, BRCA2, or TP53. 
Statistical analysis 
The baseline risk factor questionnaires that were completed at enrolment into the 
cohorts, participants were asked about their height, their current weight and their weight 
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when aged between 18 and 21 years (or at age 20 years for the ACCFR). BMI at baseline and 
BMI aged 18 to 21 years were calculated as current weight (kg) and weight aged 18 to 21 
years (kg), respectively, divided by the square of height (m) at baseline. Because there were 
so few missing values for the other risk factor questions used in analyses – 1 for smoking and 
19 for HRT use – these were taken to be non-smokers or non-users, respectively. 
We considered each BMI measure separately and then together. We calculated change 
in BMI (from age 18 to 21 years up to baseline data collection) as the difference in the two 
BMI measures, and fitted that measure alone and then combined with one or other of the two 
other measures. Note that knowing any two of the BMI measures defines the third.  
For each eligible participant, we estimated genetic risk using BOADICEA to calculate 
the lifetime risk (from birth) of invasive breast cancer (4, 5) using baseline pedigree 
information from all participating and non-participating family members and Australian 
cancer incidence rates (6). To ensure that BOADICEA lifetime risk scores could be 
calculated for all eligible participants, missing pedigree data was imputed using a previously 
developed protocol (14, 24).  We adjusted BOADICEA lifetime risk for baseline age as a 
quadratic because we want to compare women of the same age, and as a woman gets older, 
her living relatives also get older and her cancer family history becomes more informative. 
Time in the study began at the date of the baseline interview and ended at whichever 
came first of last follow-up questionnaire, diagnosis of invasive breast cancer, death, 
mastectomy, oophorectomy, or age 80 years. 
We fitted Cox proportional hazards models with age as the time axis and stratified by 
age at interview in two-year groups to estimate hazard ratios (HRs) for the risk of invasive 
breast cancer. Because our eligible participants included families with multiple members, 
robust estimates of confidence intervals (CI) were calculated by clustering by family. Tests of 
the proportional hazards assumption were based on Schoenfeld residuals. 
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We tested evidence for multiplicative gene–environment interactions using interaction 
terms created by multiplying each BMI measure by the BOADICEA lifetime risk score 
adjusted for a quadratic function of age at baseline data collection. We then included one or 
both of these interaction terms in the models.  
Stata version 13 was used for all statistical analyses (25). All statistical tests were two-
sided and P values < 0.05 were considered nominally statistically significant.  
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RESULTS 
We studied 9,126 participants from 3,222 families. On average, participants were aged 
45.9 years (standard deviation [SD] = 15.0) at baseline and contributed 10.0 years (SD = 4.1) 
of follow-up time, during which 288 invasive breast cancers were diagnosed at a mean age of 
56.6 years (SD = 12.3); Table 1 for more detail on the cohort. 
Table 2 shows the distributions, unadjusted HRs and corresponding 95% CI and P 
values for the participants’ baseline BOADICEA lifetime risk scores, BMI measures, and risk 
factor questions. For the risk factors originally measured on a continuous scale, the means 
(SD) were: 13.2% (SD = 5.5) for BOADICEA lifetime risk; 21.5 kg/m2 (SD = 3.6) for BMI 
aged 18 to 21 years; 25.2 kg/m2 (SD = 5.4) for BMI at baseline; 3.6 kg/m2 (SD = 4.6) for 
change in BMI since age 18 to 21 years; 13.0 years (SD = 1.5) for age at menarche; and 2.0 
(SD = 1.7) for number of live births. 
Breast cancer risk increased with unadjusted BOADICEA lifetime risk and with having 
a first-degree relative with breast cancer (Table 2). The HRs for the continuous measurements 
were: 1.24 (95% CI: 1.14, 1.35; P < 0.001) for each 5% of BOADICEA lifetime risk; 1.07 
(95% CI: 0.97, 1.19; P = 0.2) for each 5 kg/m2 of BMI at baseline; 0.94 (95% CI: 0.79, 1.12; 
P = 0.5) for each 5 kg/m2 of BMI aged 18 to 21 years; 1.13 (95% CI: 1.02, 1.26; P = 0.02) for 
each 5 kg/m2 change in BMI since age 18 to 21 years; 0.97 (95% CI: 0.91, 1.05; P = 0.5) for 
each year of age at menarche; and 1.00 (95% CI: 0.92, 1.08; P = 1.0) for each live birth. We 
also fitted models that allowed the BMI associations to depend on age at baseline but did not 
find any statistically significant effect modifications (data not shown). 
Table 3 shows the fits for combinations of the BMI measures, age-adjusted 
BOADICEA, and their multiplicative interactions. Models I–III show that the only BMI 
measure associated with risk on its own was the change from BMI at 18–21 years to baseline 
(P = 0.03). Model IV shows that age-adjusted BOADICEA was strongly associated with 
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breast cancer risk (P < 0.001), and comparison with models V–VII show that this association 
did not change after adjusting for the BMI measures one at a time. Similarly, comparisons of 
models V–VII with models I–III, show that the BMI associations were unchanged after 
adjusting for age-adjusted BOADICEA. 
Models VIII–X show that there was no evidence for a multiplicative interaction 
between any BMI measure and age-adjusted BOADICEA when considered alone (all P > 
0.1).  
Models XI–XIII considered the pairs of BMI measures, and all three gave similar fits 
with the same associations with age-adjusted BOADICEA. The associations with BMI at 18–
21 years and BMI at baseline both diverge from the null when fitted together (models XI 
compared with models V and VI). After adjusting for BMI at 18–21 years, both BMI at 
baseline and BMI change were associated with an increased risk of breast cancer (both P = 
0.03).  
Models XIV–XVI considered the pairs of BMI measures, this time allowing for each 
measure to have a multiplicative interaction with age-adjusted BOADICEA (all models gave 
similar fits). After adjusting for BMI at 18–21 years, both BMI at baseline and BMI change 
were associated with an increased risk of breast cancer (P = 0.04). The change in likelihood 
from models XI–XIII to models XIV–XVI was not significant (P = 0.4). 
We repeated the modeling in Table 3 after excluding women from the ACCFR who had 
colorectal cancer at baseline and found no change to the results (data not shown). We also 
repeated the modeling in after stratifying by menopausal status (Table 4). 
Figures 1 and 2 show the associations predicted by the two interaction models XIV and 
XV that include BMI at 18–21 years. Log HR estimates for both BMI measures tended to 
decrease with increasing age-adjusted BOADICEA. To illustrate interpretations, ignoring the 
lack of statistical evidence for multiplicative interactions, the predictions from these model 
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fits would be: (i) for women in the lower quartiles of age-adjusted BOADICEA, after taking 
into account BMI at age 18–21 years, both BMI at baseline and change in BMI, were 
associated with an increased risk of breast cancer, and (ii) for women in the upper quartile of 
age-adjusted BOADICEA, BMI at age 18–21 years was associated with a decreased risk of 
breast cancer.  
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DISCUSSION 
These analyses show how evidence for multiplicative gene–environment interactions 
can be assessed using family history data to predict underlying genetic risk. Non-
multiplicative interactions or interactions involving individual SNPs could have been 
similarly considered by changing the model parameterization. We age-adjusted lifetime risk 
estimated by BOADICEA as a surrogate for genetic risk because the lifetime risk predicted 
from family history increases with age and because we compared risk factors for women of 
the same age. 
Even a null finding (not finding evidence of gene–environment interactions) is 
important because it could be used to support current practice that typically assumes that the 
risk factors for the general population apply to people at high genetic risk. An increase in the 
absolute gradient in relative risk for people at higher genetic risk would have important 
implications because the gradient in absolute risk will be much greater for people at high 
genetic risk than it would be for the general population. A decrease in the absolute gradient in 
relative risk for people at higher genetic risk would also be important because this 
information could curtail inappropriate interventions and false advice for those at the higher 
end of the risk spectrum.  
Most studies of BMI and breast cancer risk use cohorts of women at average risk and 
have little statistical power to evaluate gene–environment interactions across the spectrum of 
risk. Using cohorts enriched for familial risk could help, as could better measures of family 
history risk and better measures of genetic risk. We used a prospective family cohort design 
that has increased information on familial and genetic risk by studying multiple people in the 
same family (9). We have also used a cohort enriched for genetic risk of breast cancer 
through having over-sampled women with a family history of breast cancer. This gives more 
power by increasing the proportion of women at the upper end of the highly skewed genetic 
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risk distribution. An early example of this approach in the context of a case–control study 
was by Becher et al. (26).  
Our null findings should not be taken as showing there are no multiplicative gene–
environment interactions. There were 288 incident cases, so power was limited. We did not 
find any evidence that the BMI associations depended on age at baseline, when there is strong 
evidence that this is the case at least for BMI at baseline. We did find, however, that there 
was evidence consistent with negative confounding between a protective association of BMI 
at 18–21 years and the opposite for BMI in later adulthood. Our measures of BMI at 18–21 
years likely had greater imprecision than the measure of BMI at baseline, so there would have 
been less power to detect associations and interactions of the same magnitude for the latter 
BMI measure.  
Our analyses can be used to predict statistical power for similarly structured cohorts. 
For example, the standard errors of the log(HR) for the BOADICEA interaction terms in 
Table 3 were 0.04 for models IX and X, so for these variables there was 80% power at 
significance level 0.05 (two-sided) to detect interactions of HR = 1.1 or more from this 
sample size. Given that standard errors are approximately inversely proportional to the square 
root of the number of incident cases, the detectable interaction HR would be 1.06 for 1,000 
incident cases and 1.03 for 4,000 incident cases.   
We chose BMI because it is a potentially modifiable risk factor. Having a greater BMI 
has been shown to be associated with an increased risk of breast cancer for post-menopausal 
women (27-29), especially for women who are 15 years or more post-menopause (30) or 
aged 60 years or older (31). For pre-menopausal women, the risk associated with BMI is less 
clear (27). One recent meta-analysis of studies of risk for pre-menopausal women concluded 
that having a greater BMI was associated with a decreased risk of breast cancer (29), while 
another found that the inverse risk association with BMI was not statistically significant (28). 
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Greater BMI in childhood or adolescence has been found to be associated with decreased risk 
of both pre-menopausal and post-menopausal breast cancer (27), although a recent study has 
found no evidence for an association between BMI at age 18 to 21 years and post-
menopausal breast cancer (32). 
Given the emergence of better predictors of inherent risk by including genetic risk 
scores based on SNPs, the approach demonstrated here will be increasingly important, 
especially now that many of the major cohort studies across the world are including genetic 
risk measures. It is straightforward to include measured genetic risk factors into this 
prediction, as we have recently demonstrated (3). Genetic risk scores are likely to improve 
with the use of analytic approaches that focus on predicting risk (as distinct from discovering 
risk variants), for example, by using different techniques for selecting SNPs such as gene-
based or pathway-based analyses of genome-wide association studies. Risk prediction will 
also improve by using more SNPs (33). This will all contribute to giving more power for 
detecting gene–environment interactions. In summary, we have demonstrated the power with 
which gene–environment interactions can be investigated using a cohort enriched for 
individuals with increased genetic risk and a continuous measure of genetic risk based on 
family history. We plan to use the techniques in this paper to study other potential 
multiplicative gene–environment interactions for breast cancer using a much larger 
prospective family study cohort enriched for familial risk by including families from the USA 
and Canada (9), and using other cohorts from the Cancer Cohort Consortium (34). We think 
the approach demonstrated here is timely for the upcoming era of precision health. 
 
(3,893 words) 
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FIGURE LEGENDS 
Figure 1. Plots of the logarithm of the adjusted hazard ratios (HR) and corresponding 95% 
confidence intervals for the risk of breast cancer for body mass index (BMI) at baseline per 5 
kg/m2 and BMI aged 18–21 years per 5 kg/m2 for quartiles of age-adjusted BOADICEA 
lifetime risk score, ABCFR, kConFab, and ACCFR, Australia, 1992–2010.  
 
Figure 2. Plots of the logarithm of the adjusted hazard ratios (HR) and corresponding 95% 
confidence intervals for the risk of breast cancer for change in body mass index (BMI) since 
baseline per 5 kg/m2 and BMI aged 18–21 years per 5 kg/m2 for quartiles of age-adjusted 
BOADICEA lifetime risk score, ABCFR, kConFab, and ACCFR, Australia, 1992–2010.  
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TABLES 
Table 1. Number of Families, Participants and Breast Cancers, and the Means and Standard Deviations for Number of Participants per Family, 
Age at Baseline, Years of Follow-Up, and Age at Diagnosis, by Source of Proband, ABCFR, kConFab, and ACCFR, Australia, 1992–2010. 
Source of Proband Families Participants 
Participants  
per Family 
Age at Baseline  
(years) 
Years of  
Follow-Up 
Breast  
Cancers 
Age at Diagnosis  
(years) 
 No. No.  Mean (SD) Mean (SD) Mean (SD) No. Mean (SD) 
ABCFR cases <40 years  418  1,168  2.8 (1.9)  50.7 (14.9)  14.1 (3.5)  64  62.7 (11.8) 
ABCFR cases 40–49 years  254  571  2.2 (1.4)  47.3 (17.6)  13.6 (3.0)  31  58.0 (13.6) 
ABCFR cases 50–59 years  225  556  2.5 (1.5)  43.2 (16.8)  14.0 (2.7)  20  57.9 (12.5) 
ABCFR population controls <40 years  157  433  2.8 (1.6)  44.2 (14.5)  12.3 (1.9)  12  51.9 (12.2) 
ABCFR population controls 40–49 years  154  359  2.3 (1.2)  45.6 (13.5)  11.7 (1.9)  9  58.6 (10.7) 
ABCFR population controls 50–59 years  167  401  2.4 (1.5)  46.3 (14.8)  12.1 (2.0)  10  61.3 (10.1) 
ABCFR twins  14  53  3.8 (2.4)  45.2 (15.1)  13.2 (2.2)  2  44.5 (4.9) 
ABCFR Ashkenazi  56  64  1.1 (0.4)  43.9 (11.4)  15.2 (2.0)  4  54.0 (9.8) 
kConFab  637  1,925  3.0 (2.2)  44.6 (14.6)  7.1 (3.3)  80  52.0 (11.3) 
ACCFR cases <45 years  246  566  2.3 (1.5)  43.9 (14.8)  8.0 (2.9)  8  52.4 (12.5) 
ACCFR cases 45–59 years  437  1,141  2.6 (1.7)  45.7 (14.5)  8.9 (2.5)  25  56.3 (11.1) 
ACCFR clinic-based  457  1,889  4.1 (3.4)  45.8 (14.2)  7.8 (3.0)  23  55.4 (12.3) 
Total  3,222  9,126  2.8 (2.2)  45.9 (15.0)  10.0 (4.1)  288  56.6 (12.3) 
 
Abbreviations: ABCFR, Australian Breast Cancer Family Registry; ACCFR, Australasian Colorectal Cancer Family Registry; kConFab, Kathleen Cuningham Foundation 
Consortium for Research into Familial Breast Cancer; SD, standard deviation. 
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Table 2. Frequency Distributions and Unadjusted Hazard Ratios, 95% Confidence Intervals, 
and P Values for the BOADICEA Risk Scores, Body Mass Index Measures, and Risk Factor 
Questions, ABCFR, kConFab, and ACCFR, Australia, 1992–2010. 
Risk Factor No. % HR 95% CI P value 
BOADICEA lifetime riska, %      
 Q1: 0.29 to 9.51  2,228  24.4  Referent   
 Q2: 9.52 to 11.03  2,301  25.2  1.01 0.65, 1.58  1.0 
 Q3: 11.04 to 16.27  2,287  25.1  1.81 1.27, 2.58  0.001 
 Q4: 16.28 to 59.09  2,310  25.3  2.16 1.52, 3.06  <0.001 
Body mass indexb aged 18–21 yearsc      
 Q1: 11.34 to 19.15  2,181  23.9  Referent   
 Q2: 19.16 to 20.93  2,382  26.1  1.03 0.75, 1.42  0.8 
 Q3: 20.94 to 23.06  2,280  25.0  0.89 0.64, 1.25  0.5 
 Q4: 23.07 to 68.69  2,283  25.0  0.92 0.66, 1.30  0.7 
Body mass indexd, kg/m2      
 Q1: 11.72 to 21.45  2,230  24.4  Referent   
 Q2: 21.46 to 24.02  2,324  25.5  1.18 0.84, 1.66  0.3 
 Q3: 24.03 to 27.68  2,276  24.9  1.34 0.94, 1.91  0.1 
 Q4: 27.69 to 65.75  2,296  25.2  1.26 0.88, 1.81  0.2 
Change in body mass indexe      
 Q1: −45.18 to 0.39  2,281  25.0  Referent   
 Q2: 0.40 to 2.71  2,380  25.0  1.16 0.78, 1.72  0.5 
 Q3: 2.72 to 5.86  2,270  24.9  1.56 1.09, 2.24  0.02 
 Q4: 5.87 to 40.40  2,295  25.1  1.52 1.05, 2.19  0.03 
Country of birth      
 Australia  7,430  81.4  Referent   
 Overseas  1,693  18.6  0.79 0.59, 1.07  0.1 
 Missing  3  0.0    
Education, highest completed      
 Year 10  1,908  20.9  Referent   
 Year 11–12 or vocational  4,216  46.2  0.91 0.66, 1.26  0.6 
 University degree  2,981  32.7  0.90 0.64, 1.27  0.5 
 Missing  21  0.2    
Marital status      
 Never married  1,365  15.0  Referent   
 Married or living as married  7,748  84.9  1.28 0.75, 2.17  0.4 
 Missing  13  0.1    
Age at menarche, years      
 <12  1,389  15.2  Referent   
 12  1,931  21.2  1.03 0.71, 1.49  0.9 
 13  2,522  27.6  0.98 0.69, 1.40  0.9 
 14  1,762  19.3  1.03 0.71, 1.49  0.9 
 ≥15  1,470  16.1  0.77 0.50, 1.17  0.2 
 Missing  52  0.6    
Pregnant, ever      
 No  1,865  20.4  Referent   
 Yes  7,261  79.6  1.11 0.75, 1.63  0.6 
Live birth, ever      
 No  2,267  24.8  Referent   
 Yes  6,859  75.2  1.10 0.76, 1.58  0.6 
30 
Risk Factor No. % HR 95% CI P value 
Number of live births      
 0  2,267  24.8  Referent   
 1  946  10.4  1.19 0.73, 1.91  0.5 
 2  2,499  27.4  1.10 0.73, 1.65  0.6 
 3  1,966  21.5  1.13 0.75, 1.70  0.6 
 ≥4  1,447  15.9  0.95 0.60, 1.50  0.8 
 Missing  1  0.0    
Oral contraceptive use, ever      
 No  1,931  21.2  Referent   
 Yes  7,192  78.8    
 Missing  3  0.0  1.06 0.77, 1.45  0.7 
Menopause      
 No  5,465  59.9  Referent   
 Yes  3,661  40.1  0.71 0.41, 1.24  0.2 
Hormone replacement therapy use, ever      
 No  7,333  80.4  Referent   
 Yes  1,774  19.4  1.33 0.99, 1.77  0.05 
 Missing  19  0.2    
Breast cancer in a first-degree relative      
 No  5,267  57.7  Referent   
 Yes  3,859  42.3  1.95 1.52, 2.50  <0.001 
Smoking      
 Never  4,968  54.4  Referent   
 Past  2,557  28.0  1.08 0.83, 1.39  0.6 
 Current  1,600  17.5  0.68 0.46, 1.00  0.05 
 Missing  1  0.0    
Drink alcohol, ever      
 No  3,626  39.7  Referent   
 Yes  5,496  60.2  0.95 0.75, 1.20  0.7 
 Missing  4  0.0    
 
Abbreviations: ABCFR, Australian Breast Cancer Family Registry; ACCFR, Australasian Colorectal Cancer 
Family Registry; BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation 
Algorithm; CI, confidence interval; HR, hazard ratio; kConFab, Kathleen Cuningham Foundation Consortium 
for Research into Familial Breast Cancer; Q, quartile. 
a BOADICEA risk score was divided into quartiles with the following medians: Q1, 9.09%; Q2, 9.86%; Q3, 
13.74%; and Q4, 18.74%. 
b kg/m2 
c Body mass index aged 18–21 years was divided into quartiles with the following medians: Q1, 18.25; Q2, 
20.20; Q3, 21.91; and Q4, 24.91. 
d Body mass index was divided into quartiles with the following medians: Q1, 19.95; Q2, 22.66; Q3, 25.56; and 
Q4, 31.17. 
e Change in body mass index was divided into quartiles with the following medians: Q1, 0.00; Q2, 1.63; Q3, 
4.06; and Q4, 8.65. 
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Table 3. Adjusted Hazard Ratios, 95% Confidence Intervals, and P Values for the Risk of Breast Cancer for Body Mass Index and BOADICEA 
Risk Score, ABCFR, kConFab, and ACCFR, Australia, 1992–2010.  
Model and Adjustment Criteria HRa 95% CI P Δ LLb 
I     0.17 
 BMI  at 18–21 years (per 5 kg/m2)  0.95  0.80, 1.13  0.5  
II    0.77 
 BMI at baseline (per 5 kg/m2)  1.07  0.97, 1.19  0.2   
III    1.70 
 BMI change (per 5 kg/m2)  1.13  1.01, 1.25  0.03   
IV    9.61 
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.24  1.14, 1.35  <0.001   
V    9.76 
 BMI at 18–21 years (per 5 kg/m2)  0.95  0.80, 1.13  0.6   
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.24  1.14, 1.35  <0.001  
VI    10.57 
 BMI at baseline (per 5 kg/m2)  1.08  0.98, 1.20  0.1   
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.25  1.15, 1.36  <0.001  
VII    11.59 
 BMI change (per 5 kg/m2)  1.14  1.02, 1.27  0.02   
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.25  1.15, 1.36  <0.001  
VIII    10.40 
 BMI at 18–21 years (per 5 kg/m2)  1.02  0.85, 1.24  0.8  
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.79  0.94, 3.43  0.08   
 BMI at 18–21 years (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  0.92  0.78, 1.07  0.3  
32 
Model and Adjustment Criteria HRa 95% CI P Δ LLb 
IX    11.50 
 BMI at baseline (per 5 kg/m2)  1.14  1.01, 1.28  0.03  
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.70  1.12, 2.57  0.01   
 BMI at baseline (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  0.94  0.87, 1.02  0.1  
X    11.83 
 BMI change (per 5 kg/m2)  1.17  1.03, 1.33  0.02  
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.28  1.16, 1.42  <0.001   
 BMI change (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  0.97  0.90, 1.04  0.4  
XI    11.64 
 BMI at 18–21 years (per 5 kg/m2)  0.86  0.71, 1.03  0.1  
 BMI at baseline (per 5 kg/m2)  1.14  1.02, 1.27  0.03   
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.25  1.15, 1.36  <0.001  
XII    11.64 
 BMI at 18–21 years (per 5 kg/m2)  0.97  0.82, 1.16  0.8  
 BMI change (per 5 kg/m2)  1.14  1.02, 1.27  0.03   
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.25  1.15, 1.36  <0.001  
XIII    11.64 
 BMI at baseline (per 5 kg/m2)  0.97  0.82, 1.16  0.8  
 BMI change (per 5 kg/m2)  1.17  0.97, 1.40  0.1   
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.25  1.15, 1.36  <0.001  
33 
Model and Adjustment Criteria HRa 95% CI P Δ LLb 
XIV    12.69 
 BMI at 18–21 years (per 5 kg/m2)  0.90  0.73, 1.12  0.3  
 BMI at baseline (per 5 kg/m2)  1.18  1.04, 1.34  0.01  
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.97  0.98, 3.96  0.06   
 BMI at 18–21 years (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  0.95  0.81, 1.11  0.5  
 BMI at baseline (per 5 kg/m2) × BOADICEA (per 5%; adjusted for age and age2)  0.95  0.88, 1.04  0.3  
XV    12.69 
 BMI at 18–21 years (per 5 kg/m2)  1.06  0.87, 1.30  0.6  
 BMI change (per 5 kg/m2)  1.18  1.04, 1.34  0.01  
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.97  0.98, 3.96  0.06   
 BMI at 18–21 years (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  0.90  0.77, 1.06  0.2  
 BMI change (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  0.95  0.88, 1.04  0.3  
XVI    12.69 
 BMI at baseline (per 5 kg/m2)  1.06  0.87, 1.30  0.6  
 BMI change (per 5 kg/m2)  1.11  0.90, 1.38  0.3  
 BOADICEA (per 5%; adjusted for baseline age and age2)  1.97  0.98, 3.96  0.06   
 BMI at baseline (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  0.90  0.77, 1.06  0.2  
 BMI change (per 5 kg/m2) × BOADICEA (per 5%; adjusted for baseline age and age2)  1.05  0.90, 1.23  0.5  
 
Abbreviations: ABCFR, Australian Breast Cancer Family Registry; ACCFR, Australasian Colorectal Cancer Family Registry; BMI, body mass index (kg/m2); BMI change, 
difference in body mass index (kg/m2) from age 18–21 years to baseline; BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; 
CI, confidence interval; HR, hazard ratio; kConFab, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; LL, log-likelihood. 
a Adjusted for smoking and hormone replacement therapy use. 
b Change in LL from the base model that includes smoking and hormone replacement therapy use. 
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Table 4. Adjusted Hazard Ratios, 95% Confidence Intervals, and P Values for the Risk of Breast Cancer for Body Mass Index and BOADICEA 
Risk Score by Menopausal Status, ABCFR, kConFab, and ACCFR, Australia, 1992–2010.  
 Premenopausal Postmenopausal 
Model and Adjustment Criteria HRa 95% CI P Δ LLb HRa 95% CI P Δ LLb 
I     0.34     1.78 
 BMI 18–21  1.01 0.89, 1.36  0.4   0.76 0.58, 0.99  0.04  
II     0.79     0.04 
 BMI baseline  1.10 0.96, 1.26  0.2   1.03 0.88, 1.21  0.7  
III     0.43     1.20 
 BMI change  1.10 0.93, 1.29  0.3   1.14 0.99, 1.33  0.08  
IV     7.61     2.30 
 BOADICEA  1.27 0.16, 1.40  <0.001   1.20 1.03, 1.41  0.02  
V     7.99     4.14 
 BMI 18–21  1.11 0.90, 1.37  0.3 
 
 0.76 0.58, 0.98  0.04 
 
 BOADICEA  1.26 1.16, 1.40  <0.001  1.20 1.03, 1.40  0.02 
VI     8.64     2.38 
 BMI baseline  1.11 0.97, 1.27  0.1 
 
 1.04 0.88, 1.22  0.7 
 
 BOADICEA  1.28 1.16, 1.41  <0.001  1.20 1.03, 1.41  0.02 
VII     8.24     3.64 
 BMI change  1.12 0.95, 1.31  0.2 
 
 1.15 0.99, 1.34  0.07 
 
 BOADICEA  1.28 1.16, 1.41  <0.001  1.21 1.03, 1.41  0.02 
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 Premenopausal Postmenopausal 
Model and Adjustment Criteria HRa 95% CI P Δ LLb HRa 95% CI P Δ LLb 
VIII     8.37     5.66 
 BMI 18–21  1.12 0.94, 1.53  0.1   0.89 0.67, 1.18  0.4  
 BOADICEA  1.74 0.87, 3.47  0.1   3.66 1.40, 9.58  0.008  
 BMI 18–21 × BOADICEA  0.93 0.79, 1.09  0.4   0.76 0.60, 0.97  0.03  
IX     8.72     3.60 
 BMI baseline  1.14 0.97, 1.35  0.1   1.12 0.94, 1.32  0.2  
 BOADICEA  1.44 0.88, 2.34  0.1   2.43 1.12, 5.27  0.03  
 BMI × BOADICEA  0.98 0.88, 1.08  0.6   0.87 0.75, 1.01  0.08  
X     8.26     3.79 
 BMI change  1.10 0.91, 1.33  0.3   1.19 0.99, 1.43  0.07  
 BOADICEA  1.27 1.14, 1.41  <0.001   1.27 1.00, 1.62  0.05  
 BMI change × BOADICEA  1.02 0.91, 1.13  0.8   0.95 0.83, 1.10  0.5  
XI     8.64     4.91 
 BMI 18–21  0.99 0.77, 1.28  1.0   0.70 0.53, 0.92  0.01  
 BMI baseline  1.12 0.96, 1.30  0.2   1.12 0.95, 1.32  0.2  
 BOADICEA  1.28 1.16, 1.41  <0.001   1.21 1.03, 1.41  0.02  
XII     8.64     4.91 
 BMI 18–21  1.11 0.90, 1.37  0.3   0.79 0.60, 1.04  0.09  
 BMI change  1.12 0.96,1.30  0.2   1.12 0.95, 1.32  0.2  
 BOADICEA  1.28 1.16,1.41  <0.001   1.21 1.03, 1.41  0.02  
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 Premenopausal Postmenopausal 
Model and Adjustment Criteria HRa 95% CI P Δ LLb HRa 95% CI P Δ LLb 
XIII     8.64     4.91 
 BMI baseline  1.11 0.90, 1.37  0.3   0.79 0.60, 1.04  0.09  
 BMI change  1.01 0.78, 1.29  1.0   1.42 1.08, 1.87  0.01  
 BOADICEA  1.28 1.16, 1.41  <0.001   1.21 1.03, 1.41  0.02  
XIV     12.01     6.87 
 BMI 18–21  1.08 0.83, 1.42  0.6   0.79 0.57, 1.10  0.2  
 BMI baseline  1.11 0.92, 1.33  0.3   1.17 0.97, 1.42  0.09  
 BOADICEA  1.72 0.83, 3.58  0.1   4.48 1.56, 12.90  0.005  
 BMI 18–21 × BOADICEA  0.92 0.87, 1.09  0.4   0.81 0.63, 1.05  0.1  
 BMI baseline × BOADICEA  1.01 0.91, 1.12  0.9   0.91 0.78, 1.07  0.2  
XV     12.01     6.87 
 BMI 18–21  1.20 0.94, 1.53  0.1   0.93 0.69, 1.25  0.6  
 BMI change  1.11 0.92, 1.33  0.3   1.17 0.97, 1.42  0.09  
 BOADICEA  1.72 0.83, 3.58  0.1   4.48 1.56, 12.90  0.005  
 BMI 18–21 × BOADICEA  0.93 0.79, 1.01  0.4   0.74 0.58, 0.95  0.02  
 BMI change × BOADICEA  1.01 0.91, 1.23  0.9   0.91 0.78, 0.95  0.2  
XVI     12.01     6.87 
 BMI baseline  1.20 0.94, 1.53  0.1   0.93 0.69, 1.25  0.6  
 BMI change  0.92 0.71, 1.21  0.6   1.26 0.91, 1.75  0.2  
 BOADICEA  1.72 0.83, 3.58  0.1    4.48 1.56, 12.90  0.005  
 BMI baseline × BOADICEA  0.93 0.79, 1.10  0.4   0.74 0.58, 0.95  0.02  
 BMI change × BOADICEA  1.08 0.92, 1.28  0.4   1.23 0.95, 1.59  0.1  
 
Abbreviations: ABCFR, Australian Breast Cancer Family Registry; ACCFR, Australasian Colorectal Cancer Family Registry; BMI 18–21, body mass index at age 18 to 21 
years (per 5 kg/m2); BMI baseline, body mass index at baseline (per 5 kg/m2); BMI change, difference in body mass index from age 18–21 years to baseline (per 5 kg/m2); 
37 
BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (per 5%, adjusted for baseline age and age2); CI, confidence interval; HR, 
hazard ratio; kConFab, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; LL, log-likelihood. 
a Adjusted for smoking and hormone replacement therapy use. 
b Change in LL from the base model that includes smoking and hormone replacement therapy use. 
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